Loading...
•
Dec 31, 2023
Lyell Immunopharma Q4 2023 Earnings Report
Lyell Immunopharma reported its business highlights and financial results.
Key Takeaways
Lyell Immunopharma reported a net loss of $52.9 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $562.7 million, expected to fund operations into 2027. Clinical data from lead CAR T-cell and TIL product candidates are expected in 2024, and an IND submission for a second-generation ROR1-targeted CAR T-cell product is planned for the first half of 2024.
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024.
Received Orphan Drug Designation for LYL845 for the treatment of melanoma.
Expect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2024.
Cash, cash equivalents and marketable securities of $562.7 million as of December 31, 2023 supports advancing pipeline into 2027 through multiple clinical milestones.
Lyell Immunopharma
Lyell Immunopharma
Forward Guidance
Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2027.